A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected thais

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Buranapraditkun, Supranee ^a,f   Hempel, Ursula ^b   Pitakpolrat, Patrawadee ^a   Allgaier, Rachel L ^b   Thantivorasit, Pattarawat ^a   Lorenzen, Sven Iver ^a   Sirivichayakul, Sunee ^a   Hildebrand, William H ^c   Altfeld, Marcus ^b   Brander, Christian ^d   Walker, Bruce D ^b   Phanuphak, Praphan ^a,e   Hansasuta, Pokrath ^f   Rowland Jones, Sarah L ^g   Allen, Todd M ^b   Ruxrungtham, Kiat ^a,e  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; HLA B27 ANTIGEN; HLA B57 ANTIGEN; HLA C ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOGENESIS; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; THAILAND; VIRUS STRAIN; AMINO ACID SEQUENCE; CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR GENETICS; MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; THAIS;

ADULT; ALLELES; AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CONSERVED SEQUENCE; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HLA-C ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MALE; MOLECULAR SEQUENCE DATA; MUTATION; THAILAND;

EID: 80051942027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023603     Document Type: Article

References (47)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
2. Ojikutu B, (2007) Introduction: the realities of antiretroviral therapy rollout: overcoming challenges to successful programmatic implementation. J Infect Dis 196 (Suppl 3): S445-448.
3. Larder B, (2001) Mechanisms of HIV-1 drug resistance. AIDS 15 (Suppl 5): S27-34.
4. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB, (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68: 6103-6110.
5. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650-4655.
6. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, et al. (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 94: 1890-1895.
7. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3: 205-211.
8. Ljungberg K, (2007) HIV vaccine development: the myth of Sisyphus modernized? Expert Rev Vaccines 6: 879-882.
9. Johnston MI, Fauci AS, (2007) An HIV vaccine-evolving concepts. N Engl J Med 356: 2073-2081.
10. Letvin NL, (2006) Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6: 930-939.
11. Klein J, Sato A, (2000) The HLA system. First of two parts. N Engl J Med 343: 702-709.
12. Prugnolle F, Manica A, Charpentier M, Guégan JF, Guernier V, et al. (2005) Pathogen-driven selection and worldwide HLA class I diversity. Curr Biol 15: 1022-1027.
13. Yokomaku Y, Miura H, Tomiyama H, Kawana-Tachikawa A, Takiguchi M, et al. (2004) Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 78: 1324-1332.
14. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, et al. (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354: 453-459.
15. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
16. Liu Y, McNevin J, Zhao H, Tebit DM, Troyer RM, et al. (2007) Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol 81: 12179-12188.
17. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3: 212-217.
18. Von Schwedler UK, Stray KM, Garrus JE, Sundquist WI, (2003) Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 77: 5439-5450.
19. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282-289.
20. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944-947.
21. Thomas R, Apps R, Qi Y, Gao X, Male V, et al. (2009) HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 41: 1290-1294.
22. Matucci A, Rossolillo P, Baroni M, Siccardi AG, Beretta A, et al. (2008) HLA-C increases HIV-1 infectivity and is associated with gp120. Retrovirology 5: 68.
23. Wirachsilp P, Kantakamalakul W, Foongladda S, Chuenchitra T, Kohriangudom S, et al. (2007) Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J Trop Med Public Health 38: 814-827.
24. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-23.
25. Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, et al. (2007) The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS 21 (Suppl 6): S39-46.
26. Nelson KE, Costello C, Suriyanon V, Sennun S, Duerr A, (2007) Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A_E) infection in northern Thailand, 1992-2007. AIDS 21 (Suppl 6): S47-54.
27. Kantakamalakul W, de Souza M, Bejrachandra S, Ampol S, Cox J, et al. (2006) Identification of a novel HIV type 1 CRF01_AE cytotoxic T lymphocyte (CTL) epitope restricted by an HLA-Cw0602 allele and a novel HLA-A0206/peptide restriction. AIDS Res Hum Retroviruses 22: 1271-1282.
28. Fukada K, Tomiyama H, Wasi C, Matsuda T, Kusagawa S, et al. (2002) Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. AIDS 16: 701-711.
29. Bond KB, Sriwanthana B, Hodge TW, De Groot AS, Mastro TD, et al. (2001) An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res Hum Retroviruses 17: 703-717.
30. Schneidewind A, Brockman MA, Sidney J, Wang YE, Chen H, et al. (2008) Structural and Functional Constraints Limit Options for CTL Escape in the Immunodominant HLA-B27 Restricted Epitope in HIV-1 Capsid. J Virol 82: 5594-5605.
31. Sanchez-Merino V, Farrow MA, Brewster F, Somasundaran M, Luzuriaga K, (2008) Identification and characterization of HIV-1 CD8+ T cell escape variants with impaired fitness. J Infect Dis 197: 300-308.
32. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, et al. (2006) HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med 3: e403.
33. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, et al. (2009) Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 83: 7641-7648.
34. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97: 2709-2714.
35. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, et al. (2007) Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 81: 12382-12393.
36. Kaslow RA, Carrington M, Apple R, Park L, Muñoz A, et al. (1996) Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2: 405-411.
37. Specht A, Telenti A, Martinez R, Fellay J, Bailes E, et al. (2010) Counteraction of HLA-C-mediated immune control of HIV-1 by Nef. J Virol 84: 7300-7311.
38. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D, (1998) HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391: 397-401.
39. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, et al. (1999) The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10: 661-671.
40. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
41. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
42. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
43. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
44. Korber BT, Letvin NL, Haynes BF, (2009) T cell Vaccine Strategies for HIV, the Virus With a Thousand Faces. J Virol 83: 8300-8314.
45. Lau KA, Wang B, Saksena NK, (2007) Emerging trends of HIV epidemiology in Asia. AIDS Rev 9: 218-229.
46. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, et al. (2002) Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76: 8757-8768.
47. Addo MM, Altfeld M, Rathod A, Yu M, Yu XG, et al. (2002) HIV-1 Vpu represents a minor target for cytotoxic T lymphocytes in HIV-1-infection. AIDS 16: 1071-1073.